Clinical Trial Update: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of BGB-21447, a Bcl-2 inhibitor developed by BeOne Medicines, evaluating safety and preliminary activity in multiple mature B-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Richter Transformation
• Small Lymphocytic Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• BGB-21447 (BGB-21447)

Snippet

Sponsor: BeOne Medicines | Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING